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f Discordant Creatine Kinase-MB
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or the CRUSADE Investigators
urham, Chapel Hill, and Winston-Salem, North Carolina; Baltimore, Maryland; Philadelphia, Pennsylvania;
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OBJECTIVES We sought to evaluate the association between discordant cardiac marker results and
in-hospital mortality and treatment patterns in patients with non–ST-segment elevation
acute coronary syndromes (NSTE ACS).
BACKGROUND Creatine kinase-MB (CK-MB) and cardiac troponins (cTn) are often measured concurrently
in patients with NSTE ACS. The significance of discordant CK-MB and cTn results is
unknown.
METHODS Among 29,357 ACS patients in the CRUSADE initiative who had both CK-MB and cTn
measured during the first 36 hours, we examined relationships of four marker combinations
(CK-MB/cTn, CK-MB/cTn, CK-MB/cTn, and CK-MB/cTn) with mor-
tality and American College of Cardiology/American Heart Association guidelines-
recommended acute care.
RESULTS The CK-MB and cTn results were discordant in 28% of patients (CK-MB/cTn, 10%;
CK-MB/cTn, 18%). In-hospital mortality was 2.7% among CK-MB/cTn patients;
3.0%, CK-MB/cTn; 4.5%, CK-MB/cTn; and 5.9%, CK-MB/cTn. After ad-
justment for other presenting risk factors, patients with CK-MB/cTn had a mortality
odds ratio (OR) of 1.02 (95% confidence interval [CI] 0.75 to 1.38), those with CK-MB/
cTn had an OR of 1.15 (95% CI 0.86 to 1.54), and those with CK-MB/cTn had an
OR of 1.53 (95% CI 1.18 to 1.98). Despite variable risk, patients with CK-MB/cTn and
CK-MB/cTn were treated similarly with early antithrombotic agents and catheter-based
interventions.
CONCLUSIONS Among patients with NSTE ACS, an elevated troponin level identifies patients at increased
acute risk regardless of CK-MB status, but an isolated CK-MB status has limited
prognostic value. Recognition of these risk differences may contribute to more appropriate
early use of antithrombotic therapy and invasive management for all cTn patients. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.062Coll Cardiol 2006;47:312–8) © 2006 by the American College of Cardiology Foundation
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mardiac marker testing is a fundamental component of both
iagnosis and risk stratification in patients presenting with
ymptoms suggestive of an acute coronary syndrome (ACS).
he recent European Society of Cardiology/American Col-
ege of Cardiology recommendation for redefinition of
yocardial infarction established cardiac troponin (cTn)
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niversity of North Carolina-Chapel Hill, Chapel Hill, North Carolina; ‡Depart-
ent of Pathology, University of Maryland, Baltimore, Maryland; §Department of
mergency Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania; Depart-
ent of Emergency Medicine, Wake Forest University Health Sciences, Winston-
alem, North Carolina; ¶Department of Emergency Medicine, Cleveland Clinic
oundation, Cleveland, Ohio; **Division of Cardiology, Medical College of Virginia
nd Veterans Administration Medical Center, Richmond, Virginia; and the ††De-
artment of Emergency Medicine, University of Cincinnati College of Medicine,
incinnati, Ohio. The CRUSADE investigation is a National Quality Improvement
nitiative of the Duke Clinical Research Institute and is funded by Millennium
harmaceuticals Inc., Cambridge, Massachusetts, and Schering Corp., Kenilworth,
ew Jersey. The Bristol-Myers Squibb (Plainsboro, New Jersey)/Sanofi Pharmaceu-
icals (New York, New York) Partnership provided additional funding support.C
Manuscript received May 18, 2005; revised manuscript received July 24, 2005,
ccepted August 1, 2005.esting as the “gold standard” for diagnosis (1), and its
uperiority over other biomarkers for risk stratification has
een demonstrated in numerous studies using core labora-
ories (2–6). In addition, several studies using core labora-
ory cTn testing have defined treatment benefit for several
herapies based on a positive (1 upper limit of normal
ULN]) or negative (1 ULN) result (7–14). Despite
hese data, use of creatine kinase-MB (CK-MB) testing in
linical practice remains commonplace, and often cTn and
K-MB levels are both tested.
Although dual testing is often performed, physicians have
oncerns about false positive cTn results and often question
he prognostic value of cTn in the absence of a positive
K-MB result. Similarly, studies examining the risks asso-
iated with an “isolated elevated CK-MB” result have been
onflicting, in part because of limited study size and
ethodology (15,16). Thus, a better understanding of the
isks associated with concordant and discordant cardiac
arkers could lead to improved application of American
ollege of Cardiology (ACC)/American Heart Association
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313JACC Vol. 47, No. 2, 2006 Newby et al.
January 17, 2006:312–8 Discordant Cardiac Markers in NSTE ACSAHA) guidelines-recommended management of patients
ith non–ST-segment elevation (NSTE) ACS (17,18).
We investigated the use of dual cardiac marker testing in
linical practice, including the frequency of discordant
esults and the association of the results with in-hospital
ortality and ACC/AHA guidelines-recommended acute
edication and invasive procedure use among NSTE ACS
atients who were enrolled in the Can Rapid Risk Stratifi-
ation of Unstable Angina Patients Suppress Adverse Out-
omes with Early Implementation of the ACC/AHA
uidelines (CRUSADE) Quality Improvement Initiative.
ETHODS
tudy population. The study population for our analysis
omprised 29,357 patients with high-risk NSTE ACS who
resented directly to one of 396 U.S. hospitals participating
n the CRUSADE Initiative. We excluded patients who
ransferred in from another hospital (because of difficulty in
iming cardiac marker assessment) and those who trans-
erred out to another hospital (as their outcomes could not
e tracked because of U.S. privacy laws). The inclusion
riteria and data collection methods for the CRUSADE
nitiative have been described in detail elsewhere (19).
riefly, patients with symptoms of ACS for at least 10 min
ho presented within 24 h of onset and who had either
lectrocardiographic changes consistent with a diagnosis of
schemia (transient ST-segment elevation 0.5 to 1.0 mm
lasting for 10 min], ST-segment depression 0.5 mm)
r elevation of either cTn or CK-MB to greater than the
alue reported by a site’s local laboratory to designate
efinite myocardial necrosis or a positive bedside cardiac
arker assay were included in the CRUSADE Initiative. A
ata collection form was used to gather information on
aseline demographic and clinical characteristics, cardiac
arker results, medication and procedure use, and in-
ospital outcomes for all enrolled patients. Only baseline
nd peak cardiac marker results (including time of peak
easurement) were recorded on the CRUSADE data
ollection form. All patients in the present analysis had both
aseline and peak cTn and CK-MB values recorded. Data
Abbreviations and Acronyms
ACC  American College of Cardiology/
ACS  acute coronary syndrome
AHA  American Heart Association
CI  confidence interval
CK-MB  creatine kinase-MB
CRUSADE  Can Rapid Risk stratification of Unstable
Angina Patients Suppress Adverse
Outcomes with Early Implementation of
the ACC/AHA Guidelines
cTn  cardiac troponin
NSTE  non–ST-segment elevation
OR  odds ratio
ULN  upper limit of normalere collected anonymously during the initial hospitaliza- aion, and because no patient identifiers are collected, indi-
idual informed consent was not required. The institutional
eview board of each institution approved participation in
he CRUSADE Initiative.
arker status and outcomes of interest. We determined
he frequency of discordant cTn and CK-MB results among
atients with peak measurements within 36 h of patient
resentation. Creatine kinase-MB and cTn were considered
ositive when any reported value (baseline or peak) exceeded
he ULN for the assays used in the site’s local laboratory.
atients were partitioned into four groups on the basis of
hese results: both markers negative (CK-MB/cTn),
K-MB positive and cTn negative (CK-MB/cTn),
K-MB negative and cTn positive (CK-MB/cTn), and
oth markers positive (CK-MB/cTn). We then inves-
igated the relationship of each marker category with
n-hospital mortality and with acute use of ACC/AHA
uidelines-recommended medical therapies (24 h of pre-
entation) and an early invasive management strategy
within 24 to 48 h of presentation).
tatistical methods. Baseline characteristics, medical
reatment, procedure use, and in-hospital outcomes were
ompared across the four CK-MB/cTn categories. Contin-
ous variables were reported as medians with 25th and 75th
ercentiles, and categorical variables were reported as fre-
uencies. Continuous variables were compared using the
ruskal-Wallis test, and categorical variables were com-
ared using the chi-square test.
In examining the relationship between the CK-MB/cTn
ategories and care patterns and outcomes, we initially
erformed unadjusted comparisons. We then adjusted for a
road range of patient and hospital characteristics, including
emographic, clinical, and hospital variables, using gener-
lized estimating equation models to account for correla-
ions among clustered responses (e.g., within-hospital cor-
elations) (20, 21). All odds ratios (ORs) were reported with
K-MB/cTn as the reference group.
Finally, as troponin results can also be elevated among
hose with renal failure, which could inflate their prognostic
alue, we performed a sensitivity analysis by repeating all
nalyses after excluding patients with renal insufficiency or
or whom data on renal insufficiency were missing (n 
,821). A p value of 0.05 was established as the level of
tatistical significance for all tests. All analyses were per-
ormed using SAS software (versions 8.2, SAS Institute,
ary, North Carolina).
ESULTS
atient population. Among 29,357 patients with NSTE
CS, 22,867 were cTn and 20,506 were CK-MB. The
ajority of patients had concordant cardiac marker results as
,502 (11.9%) were CK-MB/cTn and 17,518 (59.7%)
ere CK-MB/cTn. In 28% of patients, CK-MB and cTn
esults were discordant (n  2,988 [10.2%] CK-MB/cTn
nd n  5,349 [18.2%] CK-MB/cTn).
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Discordant Cardiac Markers in NSTE ACS January 17, 2006:312–8Table 1 displays the baseline characteristics of the study
opulation by cardiac marker category. Patients in the
Tn groups were older regardless of CK-MB status; more
ften had prior stroke and renal insufficiency; and had
igher heart rate, lower blood pressure, and, more fre-
uently, signs of heart failure at presentation. They were
lso more likely to receive cardiology consultation during
able 1. Baseline Characteristics by Cardiac Marker Category
CK-MB/cTn
(n  3,502)
emographics
Age, yrs 66 (55, 77)
Female gender 47.9
Race
White 77.0
Black 15.6
Asian 1.5
Hispanic 3.2
Other 1.9
Body mass index, kg/m2 28 (24, 32)
Insurance status
HMO/private 44.5
Medicare/Medicaid 48.2
Self/none 6.2
edical history and risk factors
Family history of CAD 42.0
Hypertension 74.8
Diabetes mellitus 32.4
Current/recent smoker 25.4
Hypercholesterolemia 50.5
Prior myocardial infarction 34.1
Prior PCI 32.6
Prior CABG 25.6
Heart failure 17.0
Stroke 9.8
Renal insufficiency 10.5
linical presentation
Electrocardiogram
ST-segment depression 76.2
Transient ST-segment elevation 14.6
Type of troponin
Baseline
Troponin I 84.2
Troponin T 13.8
Peak
Troponin I 70.9
Troponin T 11.6
Signs of heart failure 15.0
Heart rate, beats/min 79 (68, 94)
Systolic blood pressure, mm Hg 148 (128, 168)
Time from symptom onset, h 2.9 (1.3, 7.0)
are patterns
Cardiology care primary 56.9
Hospital features
Academic hospital 24.3
Total hospital beds 350 (245, 490)
Cath laboratory only 8.1
PCI, no bypass surgery 7.3
CABG 79.8
alues are % or median (25th, 75th percentile).
CABG coronary artery bypass grafting; CAD coronary artery disease; Cath
aintenance organization; PCI  percutaneous coronary intervention.heir hospitalization and be enrolled at larger hospitals. The aK-MB patients were more often male and less often had
rior myocardial infarction regardless of cTn status. Groups
ith discordant cardiac markers had a greater proportion of
acial/ethnic minorities. All marker-positive groups had
ower proportions of patients with a history of coronary
rtery disease and hypertension than patients in the group
hat was negative for both markers. The use of a troponin I
-MB/cTn
(n  2,988)
CK-MB/cTn
(n  5,349)
CK-MB/cTn
(n  17,518)
66 (55, 77) 70 (57, 79) 70 (57, 80)
34.0 44.6 39.9
74.5 75.6 80.4
16.5 15.3 11.7
2.0 1.3 1.2
3.1 4.1 3.3
2.8 2.6 2.2
28 (25, 32) 27 (24, 31) 27 (24, 31)
44.3 39.5 43.8
47.3 53.5 48.4
7.3 6.2 6.7
35.6 33.6 34.7
69.9 70.8 67.5
31.5 37.1 32.5
25.6 22.9 26.7
47.0 45.5 43.8
31.6 34.1 29.9
24.3 23.4 18.6
21.5 22.1 19.1
19.1 22.3 19.5
9.4 12.6 11.4
11.0 18.3 14.1
33.3 31.9 26.1
9.4 6.0 9.4
68.5 86.2 82.1
28.6 12.7 16.6
56.9 83.2 78.6
23.7 12.4 15.3
18.4 27.1 25.4
81 (69, 96) 84 (71, 100) 86 (72, 102)
148 (129, 168) 146 (125, 167) 146 (125, 167)
2.6 (1.2, 6.2) 2.9 (1.3, 7.3) 2.8 (1.3, 7.2)
51.4 53.2 53.9
29.5 29.6 26.1
365 (241, 475) 377 (264, 532) 374 (260, 492)
5.8 8.4 8.3
5.4 7.6 5.0
85.2 79.0 82.8
terization; CK-MB creatine kinase-MB; cTn cardiac troponin; HMO healthCKssay predominated in all groups, but troponin T was used
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January 17, 2006:312–8 Discordant Cardiac Markers in NSTE ACSore frequently among patients in the CK-MB/cTn
roup compared with other groups.
After excluding 2,506 patients (8.5%) whose only positive
Tn was after a percutaneous coronary intervention, results
ere similar: 29.9% of patients had discordant marker
esults; 11.1% CK-MB/cTn and 18.8% CK-MB/
Tn. Baseline characteristics by marker category were also
imilar to those for the overall population.
linical outcomes. Considering only single-marker status,
n-hospital mortality among cTn patients was 5.5% com-
ared with 2.8% among cTn patients. In-hospital mor-
ality was 5.4% among CK-MB patients and 3.8% among
K-MB patients. In-hospital mortality was 2.7% among
K-MB/cTn patients, 3.0% among CK-MB/cTn
atients, 4.5% among CK-MB/cTn patients, and 5.9%
mong CK-MB/cTn patients. After eliminating the
,506 patients whose only positive troponin occurred after a
ercutaneous coronary intervention, mortality rates were
imilar in the cTn groups (CK-MB/cTn, 2.7% and
K-MB/cTn, 3.0%) and were only slightly higher in
he cTn groups (CK-MB/cTn, 4.6% and CK-MB/
Tn, 6.3%).
In multivariable analysis, after accounting for other base-
ine clinical and electrocardiographic factors (ST-segment
epression [chi square 8.0]) and within hospital clustering,
oth CK-MB and cTn, tested as continuous variables,
dded incremental information regarding patients’ risk for
n-hospital mortality. However, cTn was more strongly
ssociated with mortality than CK-MB (chi square 23.2 for
Tn vs. 7.6 for CK-MB). When we limited our analyses to
nly the 23,794 patients who had troponin I testing, the
esults were consistent with those in the overall population.
urther, when type of cTn (I or T) was tested in the model,
t was nonsignificant, suggesting that there was no differ-
nce in association with mortality based on the type of
roponin assayed.
Similarly, there was a clear gradient of risk among our
our categorical groupings. Relative to patients who were
egative for both markers (CK-MB/cTn), those who
ere CK-MB/cTn had a mortality OR of 1.02 (95%
onfidence interval [CI] 0.75 to 1.38); patients who were
K-MB/cTn had an OR of 1.15 (95% CI 0.86 to 1.54);
nd those who were CK-MB/cTn had an OR of 1.53
95% CI 1.18 to 1.98). After excluding patients with renal
nsufficiency or missing information on renal insufficiency,
he pattern of in-hospital mortality was similar: CK-MB/
Tn, 2.3%; CK-MB/cTn, 2.5%; CK-MB/cTn,
.4%; and CK-MB/cTn, 5.1%.
Among patients with discordant cardiac marker results,
e repeated the analysis of the continuous relationship of
Tn elevation with mortality among CK-MB patients and
he continuous relationship of CK-MB elevation with
ortality among cTn patients. Among patients with
egative cTn, in-hospital mortality was not elevated above
aseline until CK-MB exceeded four times ULN (12.8% of
ll CK-MB/cTn patients). In contrast, among CK- uB patients, in-hospital mortality was in the 4% to 5%
ange (two- to three-fold increased risk) for all elevations of
Tn 1 ULN even in the presence of a negative CK-MB
ssay.
cute use of medications and invasive management. Rates
f adherence to guidelines-recommended acute medications
nd invasive procedures are shown in Table 2, along with
djusted ORs with 95% CIs for each marker category
elative to the CK-MB/cTn group. After adjustment
or patient and hospital characteristics, the odds of use of all
uidelines-recommended acute medical therapies were con-
istently greatest among patients with both cardiac markers
ositive. However, patients with discordant CK-MB and
Tn results received acute antithrombotic therapy in nearly
dentical patterns, with both groups being treated only
lightly more aggressively than those with CK-MB/cTn
anels. For example, use of acute glycoprotein IIb/IIIa
nhibitors was 18.4% for patients with CK-MB/cTn,
3.7% in the CK-MB/cTn group, and 22.9% among
he CK-MB/cTn group. Paradoxically, an early inter-
entional strategy was actually more commonly applied to
atients with CK-MB/cTn panels relative to those with
iscordant positive cardiac marker panels. Rates of diagnos-
ic cardiac catheterization within 48 h ranged from 40% to
4.5% for the three groups (Table 2). These patterns of care
emained similar after adjustment for patient and hospital
haracteristics (Fig. 1).
ISCUSSION
e have shown that among patients with high-risk NSTE
CS managed under conditions of clinical practice, in-
ospital mortality in cTn patients is increased regardless
f CK-MB status. Although both markers contribute inde-
endent information in multivariable modeling, the overall
ontribution of troponin is stronger, and there is variability
ithin the relationship such that there is little increase in
isk at low-level CK-MB elevation. We also found that
urrent patterns of use of acute antithrombotic therapies and
n early invasive management strategy in community-based
ractice fail to reflect these risk profiles. Given higher risk
mong cTn patients and previous evidence for preferential
enefit from the use of these treatments on the basis of cTn
tatus, we should be wary of treating CK-MB/cTn
atients aggressively and focus on improving delivery of
hese treatment strategies to cTn patients regardless of
K-MB results.
arker status and outcome. Patients with both markers
ositive within 36 h of presentation were at highest risk
or in-hospital events, and those with both markers
egative were at lowest risk. Among patients with dis-
ordant results (28%), any degree of isolated troponin
levation was more consistently associated with increased
ortality than isolated CK-MB elevation, for which
ortality was similar to that with both markers negativentil CK-MB exceeded three to four times the ULN.
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Discordant Cardiac Markers in NSTE ACS January 17, 2006:312–8his may represent more biological “noise” with CK-MB
ince there is normally some present in the blood,
hereas cTn is not normally detectable, making the
pecificity of small elevations of cTn greater. As cTn
ssays become more sensitive, it is likely that CK-MB/
Tn results will become more frequent. Regardless, our
esults suggest that in clinical practice there is little
dvantage of simultaneous CK-MB and cTn testing for
isk stratification in patients with high-risk ACS presen-
ations, although a role may still remain for use of
able 2. Use of Guideline-Recommended Acute Medications* an
CK-MB/cTn
(n  3,502)
edications (first 24 h)
Aspirin, % 88.8
Adjusted OR (95% CI) —
Beta-blocker, % 69.7
Adjusted OR (95% CI) —
Heparin, any, % 70.9
Adjusted OR (95% CI) —
Unfractionated heparin, % 41.7
Adjusted OR (95% CI) —
Low molecular weight heparin, % 33.7
Adjusted OR (95% CI) —
Clopidogrel, % 32.5
Adjusted OR (95% CI) —
GP IIb/IIIa inhibitor, % 18.4
Adjusted OR (95% CI) —
rocedures
Diagnostic cardiac cath
24 h, % 26.2
Adjusted OR (95% CI) —
48 h, % 44.5
Adjusted OR (95% CI) —
PCI
Any, % 36.3
Adjusted OR (95% CI) —
24 h, % 11.8
Adjusted OR (95% CI) —
CABG surgery, % 12.0
Adjusted OR (95% CI) —
Among patients without contraindications to a given medication. †Among patients
CI  confidence interval; GP  glycoprotein; OR  odds ratio; Other abbrevia
igure 1. Odds ratios with 95% confidence intervals for acute use of
lycoprotein (GP) IIb/IIIa inhibitors, clopidogrel, and an early invasivem
anagement strategy. CK-MB  creatine kinase-MB; cTn  cardiac
roponin.K-MB in timing of infarction or defining re-infarction
r infarction associated with percutaneous coronary in-
ervention or coronary artery bypass graft surgery. The
tronger association of cardiac troponins than CK-MB
ith adverse clinical outcomes most likely reflects their
reater sensitivity and specificity for minor myocardial
ecrosis resulting from microembolization from active
laques, which predispose to subsequent major clinical
vents, but whose activity may not be detectable by less
ensitive or specific markers such as CK-MB until a
arger event occurs. The explanation for the CK-MB/
Tn discordance is more challenging. These could
eflect timing of marker testing relative to symptom onset
r discordance in timing of sampling, or simply false
egative troponin tests. It is interesting that troponin T
se was more frequent among the CK-MB/cTn
roup than in the three other marker categories. This
ay reflect the previously recommended use of a higher
OC-determined ULN for this assay relative to using a
utoff at the 99th percentile of a reference control
opulation as occurs for some troponin I assays. Recently,
he package insert for this assay was changed to reflect a
ecommended ULN of 0.03 ng/ml based on the 99th
ercentile of a reference control population and 10% CV
evel compared with the previous 0.1 ng/ml recom-
ocedures†
-MB/cTn
(n  2,988)
CK-MB/cTn
(n  5,349)
CK-MB/cTn
(n  17,518)
90.6 90.5 91.8
.15 (0.96–1.38) 1.24 (1.06–1.45) 1.41 (1.22–1.63)
69.9 75.7 79.3
.02 (0.89–1.17) 1.34 (1.20–1.51) 1.62 (1.45–1.80)
72.8 75.9 86.8
.31 (1.14–1.51) 1.56 (1.40–1.74) 2.87 (2.57–3.20)
45.5 42.6 55.2
.31 (1.14–1.50) 1.30 (1.17–1.44) 2.01 (1.80–2.24)
31.3 38.2 38.5
.92 (0.83–1.03) 1.05 (0.95–1.15) 1.06 (0.97–1.16)
33.5 33.9 40.3
.22 (1.09–1.37) 1.26 (1.15–1.37) 1.59 (1.45–1.75)
23.7 22.9 38.3
.88 (1.58–2.22) 1.89 (1.63–2.18) 3.73 (3.26–4.26)
26.5 21.7 32.5
.37 (1.13–1.66) 1.22 (1.06–1.40) 1.94 (1.68–2.23)
39.8 40.0 50.1
.09 (0.92–1.30) 1.28 (1.12–1.48) 1.79 (1.55–2.06)
34.6 33.1 41.4
.15 (0.95–1.39) 1.22 (1.03–1.45) 1.62 (1.39–1.89)
16.8 10.8 20.0
.11 (1.65–2.68) 1.47 (1.21–1.79) 2.73 (2.27–3.27)
9.2 11.0 13.1
.80 (0.66–0.98) 1.06 (0.89–1.25) 1.10 (0.95–1.28)
ed at hospitals with coronary bypass surgery capability.
s in Table 1.d Pr
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January 17, 2006:312–8 Discordant Cardiac Markers in NSTE ACSsting to see whether increased use of the 0.03 ng/ml
utoff for patients tested with this assay results in a
hange in this pattern as more patients accrue in the
atabase.
Our results among high-risk patients in clinical practice
re similar to a previous analysis of high-risk ACS patients
nrolled in clinical trials, in which baseline cTn elevation
ith or without CK-MB elevation was associated with
ncreased risk for 30-day death or myocardial infarction, and
atients with CK-MB elevation without cTn elevation had
0-day risk that was similar to patients with both markers
egative (16). However, a single-center study of 542
roponin-negative patients who were followed for six
onths for the composite endpoint of death, cardiac rehos-
italization, stroke, or myocardial infarction, revealed an
R for CK-MB/cTn relative to CK-MB/cTn of
.86 (95% CI 1.14 to 3.03) (15). The differences between
hese studies possibly reflect the timing of the end point
ssessment, with elevations of CK-MB in the absence of
Tn elevation being more sensitive for risk over the long
erm rather than acutely.
se of guideline-recommended management and marker
esults. For aspirin, beta-blockers, and clopidogrel, no
ifference in relative benefit from therapy has been demon-
trated by applying treatment based upon the results of
ardiac marker testing. Despite this, there was a tendency to
se aspirin and beta-blockers more frequently among pa-
ients who were both CK-MB and cTn or who were
K-MB/cTn; a difference that persisted even after
ccounting for differences in baseline patient characteristics
nd hospital-related factors. A tendency for more effective
pplication of evidence-based medical therapy in patients
ith acute myocardial infarction compared with unstable
ngina has been demonstrated in other databases (22,23),
ut a differential in use in patients with discordant marker
esults (CK-MB/cTn and CK-MB/cTn) relative to
oth markers being negative has not been previously
eported.
Conversely, several studies have shown that the results of
roponin testing can define high-risk groups of patients who
referentially benefit from the use of low-molecular-weight
eparin and glycoprotein IIb/IIIa inhibitors (with or with-
ut concomitant percutaneous coronary intervention) and
n early invasive management strategy (7–14). Our obser-
ations suggest that this information is not applied consis-
ently in clinical practice. Among patients with discordant
esults, there was no differential in glycoprotein IIb/IIIa use
ased on troponin status. Thus, it appears that treatment
ith glycoprotein IIb/IIIa inhibitors is biased by CK-MB
tatus despite the evidence that favors use among cTn
atients. Similarly, despite a previous analysis that showed
o interaction of CK-MB status with benefit from an early
nvasive strategy, but when stratified by troponin status
emonstrated evidence for benefit among CK-MB/cTn
atients (24), in our study, even after accounting for patient
nd hospital characteristics, CK-MB/cTn patients were 3ost likely to undergo early diagnostic cardiac catheteriza-
ion. Among those with discordant results, there was no
ifference in use of diagnostic catheterization within 24 h
nd only slightly more frequent use among CK-MB/
Tn patients than CK-MB/cTn patients in the
48-h time frame.
tudy limitations. The ACC/AHA guidelines are in con-
inual evolution as new evidence becomes available. There-
ore, it is possible that some of the relationships we observed
ay be of more or less relevance over time. Independent of
his, our findings highlight several areas for education about
isk and the application of both marker testing and
vidence-based therapies that could have a substantial im-
act on the outcomes of high-risk ACS patients in the
resent. In part, our observations may reflect issues of
ifferences in clinical trials populations and clinical practice
CS populations, perhaps reflecting uncertainty among
linicians about the benefits and risks of using antiplatelet
herapy and early invasive management strategies among
lder and sicker patients, who tended to be under-
epresented in clinical trials. Continued efforts to enhance
epresentation of these populations in future studies should
elp to better define treatment in these groups.
Since the CRUSADE population was selected on the
asis of presence of high-risk characteristics, we cannot be
ure that these findings would extend similarly to the entire
pectrum of ACS, but there is no compelling reason to
elieve that they would not.
Marker-positive status was determined by using the site’s
wn laboratory-reported ULN for comparison with baseline
nd peak values reported by the CRUSADE investigators.
roponin substudies of clinical trials have established the
esignation of positive troponins as any value above the ULN
or the assay used, and it is at these levels that the mortality
nd treatment effect differences were observed and accepted
7–9). In an attempt to examine these findings in the
ontext of clinical practice, we have applied the same
aradigm to the best available marker data. Since a core
aboratory was not used, there is unavoidable variation in the
ype, quality, and standardization of the individual troponin
ssays used across hospitals. However, we feel our observa-
ions fairly represent clinical practice and the integration of
arker testing into clinical decision making. Despite this,
nd the fact that we adjusted for hospital characteristics in
ur modeling, it remains possible that concern among
hysicians about the reliability of a reported troponin result
ay have influenced clinical management decisions, since it
ppears from our results that a positive CK-MB was
ecessary in addition to a positive cTn before more aggres-
ive care was applied.
Finally, we did not account for the timing of positive
arkers. It is possible that since we assigned patients to
arker categories based upon the highest marker level
ttained, irrespective of when it occurred within the first
6 h, physicians were less aggressive in the management of
p
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ater in that period.
onclusions. Short-term mortality in cTn patients is
ncreased regardless of CK-MB status, but CK-MB eleva-
ion in the absence of elevated cTn does not necessarily carry
he same implications. Paradoxically, some therapies that
re equally effective across all levels of risk are used more
requently in cTn patients, whereas therapies demon-
trated to be more effective among cTn patients are not
sed differentially based on marker status. Recognition of
ifferences in risk based on the results of cardiac marker
esting and the relationships of the effectiveness of available
herapies with marker status and risk should contribute to
ore appropriate early use of evidence-based treatment for
CS, particularly antiplatelet therapy and early invasive
anagement.
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